Comparative Pharmacology
Head-to-head clinical analysis: SULFAMETHOPRIM versus SULFISOXAZOLE DIOLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMETHOPRIM versus SULFISOXAZOLE DIOLAMINE.
SULFAMETHOPRIM vs SULFISOXAZOLE DIOLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoprim is a combination of sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits bacterial dihydrofolate reductase, also blocking folic acid synthesis. This sequential blockade produces bactericidal effects.
Sulfisoxazole diolamine is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Oral or intravenous: 800 mg sulfamethoxazole / 160 mg trimethoprim every 12 hours.
2-4 g orally initially, followed by 4-8 g/day in 4-6 divided doses for urinary tract infections; 6-8 g/day in 4-6 divided doses for nocardiosis.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours).
5-10 hours (prolonged in renal impairment; normal half-life in adults ~6 hours)
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary: 5-10%; fecal: <5%.
Renal: 70-100% (primarily as unchanged drug and acetylated metabolite); Biliary/Fecal: <5%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic